Clinical Trial

Novel Subtypes and Treatment Strategies of Patients with Unresectable Combined Hepatocellular Cholangiocarcinoma Based on Multimodal Data

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 27, 2025 (before its estimated November 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study focused on exploring new comprehensive treatment strategies for patients with unresectable combined hepatocellular-cholangiocarcinoma, classifying patients with CHC subtypes based on the combination of artificial intelligence and multi-omics, and exploring the optimal treatment strategies for patients with different subtypes, helping clinicians to screen the most beneficial groups of various treatment schemes, and providing new ideas for safe treatment of high-risk patients.
Trial Details
NCT Number NCT06849180
Lead Sponsor Zhongda Hospital
Collaborators: Eastern Hepatobiliary Surgery Hospital, The First Affiliated Hospital of Zhengzhou University, Jiangsu Cancer Institute & Hospital, Yunnan Cancer Hospital, Zhejiang Cancer Hospital, Shanghai Zhongshan Hospital, Sun Yat-Sen University Cancer Center
Conditions Combined Hepatocellular-cholangiocarcinoma, Combined Hepatocellular Carcinoma and Cholangiocarcinoma, Combined Hepatocellular and Cholangiocarcinoma
Enrollment 198 participants
Start Date 2024-12-31
Primary Completion 2025-11-30 (estimated)
Study Completion 2026-02-28 (estimated)
Updated on ClinicalTrials.gov 2025-02-27